Factors associated with reduced left ventricular ejection fraction in patients with primary myocardial infarction

   Objective: based on the data from the total register of acute coronary syndrome (ACS) in the Krasnodar Territory, identify the factors associated with reduced LV EF in patients with primary acute myocardial infarction (MI).

   Materials and methods: a retrospective study was conducted on 5,655 patients with primary MI included in the total ACS registry in the Krasnodar Territory from 2022 to 2024. The study examined the relationship between LV EF and the clinical, anamnestic, and diagnostic data of the patients. LV EF values were assessed using the Simpson method before discharge from the hospital or earlier in case of hospital-acquired death. Depending on the LV EF, all patients were divided into groups with low (≤ 40 %) LV EF (n = 1125), moderately low (41-49 %) LV EF (n = 1258), and preserved (≥ 50 %) LV EF (n = 3272).

   Results: the data of 5,655 patients included in the total ACS registry in the Krasnodar Territory for the period from 2022 to 2024 were analyzed. Factors such as a history of smoking, chronic kidney disease, hypertension, and peripheral atherosclerosis, increased troponin, creatinine > 130 mmol/l, and glucose > 15 mmol/l upon admission according to laboratory blood tests, and ST segment elevation and the formation of a pathological Q wave on an electrocardiogram, as well as acute heart failure (AHF) of class II–IV according to Killip and the presence of early complications of MI were identified as predictors of a decrease in LVEF in patients with primary MI.

   Conclusions: presence of smoking, chronic kidney disease, arterial hypertension and peripheral atherosclerosis in the anamnesis, increase in troponin, creatinine > 130 μmol/L and glucose > 15 mmol/L, ST segment elevation, formation of pathological Q-wave, the phenomena of OSN II–IV class according to Killip, and the presence of early complications are associated with a decrease in LV EF in patients with MI.

1. Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis G, et al. Burden of heart failure in Flemish general practices: a registry-based study in the Intego database. BMJ Open. 2019;9(1):e022972. DOI: 10.1136/bmjopen-2018-022972

2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. Erratum in: Lancet. 2019;393(10190):e44. DOI: 10.1016/S0140-6736(18)32279-7.

3. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333-1341. DOI: 10.1056/NEJMoa1406656

4. Dunlay S.M., Roger V.L. Understanding the epidemic of heart failure: past, present, and future. Curr. Heart Fail. Rep. 2014;11(4):404-415. DOI: 10.1007/s11897-014-0220-x.

5. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA. 2007;297(17):1892-1900. DOI: 10.1001/jama.297.17.1892

6. Dégano IR, Salomaa V, Veronesi G, Ferriéres J, Kirchberger I, Laks T, et al. Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations. Heart. 2015;101(17):1413-1421. Erratum in: Heart. 2018;104(16):e2. DOI: 10.1136/heartjnl-2014-307310

7. Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, Younis A, Dai H. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682-1690. DOI: 10.1093/eurjpc/zwaa147

8. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) DOI: 10.18087/cardio.2021.4.n1628

9. Hung J, Teng TH, Finn J, Knuiman M, Briffa T, Stewart S, et al. Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia. J Am Heart Assoc. 2013;2(5):e000172. DOI: 10.1161/JAHA.113.000172

10. Sulo G, Igland J, Vollset SE, Nygård O, Ebbing M, Sulo E, et al. Heart Failure Complicating Acute Myocardial Infarction; Burden and Timing of Occurrence: A Nation-wide Analysis Including 86 771 Patients From the Cardiovascular Disease in Norway (CVDNOR) Project. J Am Heart Assoc. 2016;5(1):e002667. DOI: 10.1161/JAHA.115.002667

11. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-1133. DOI: 10.1016/j.jacc.2013.11.053

12. Desta L, Jernberg T, Löfman I, Hofman-Bang C, Hagerman I, Spaak J, et al. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC Heart Fail. 2015;3(3):234-242. DOI: 10.1016/j.jchf.2014.10.007

13. Choi Y, Lee KY, Kim SH, Kim KA, Hwang BH, Choo EH, et al. Predictors for early cardiac death after discharge from successfully treated acute myocardial infarction. Front Med (Lausanne). 2023;10:1165400. DOI: 10.3389/fmed.2023.1165400

14. Gho JMIH, Schmidt AF, Pasea L, Koudstaal S, Pujades-Rodriguez M, Denaxas S, et al. An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors. BMJ Open. 2018;8(3):e018331. Erratum in: BMJ Open. 2018;8(3):e018331corr1. DOI: 10.1136/bmjopen-2017-018331

15. Karibova M.V., Kruchinova S.V., Gendugova M.N., Kosmacheva E.D. Heart failure in Krasnodar Krai: analysis of the current situation and ways to improve it. Therapy. 2025; 11(2): 17—31. (In Russ.) DOI: 10.18565/therapy.2025.2.17-31

16. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL. Heart failure after myocardial infarction : a review. Am J Med. 2002;113(4):324-330. DOI: 10.1016/s0002-9343(02)01185-3

17. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97(10A):13F-25F. DOI: 10.1016/j.amjcard.2006.03.005

18. Campo G, Saia F, Guastaroba P, Marchesini J, Varani E, Manari A, et al. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch Intern Med. 2011;171(21):1948-1949. DOI: 10.1001/archinternmed.2011.536

19. Wohlfahrt P, Jenča D, Melenovský V, Šramko M, Kotrč M, Želízko M, et al. Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions. Front Cardiovasc Med. 2022;9:1051995. DOI: 10.3389/fcvm.2022.1051995

20. Carberry J, Petrie MC, Lee MMY, Stanley B, Brooksbank KJM, Campbell RT, et al. Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). Eur J Heart Fail. 2025;27(3):566-576. DOI: 10.1002/ejhf.3560

21. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421-4432. DOI: 10.1093/eurheartj/ehac494

22. Bellis A, Mauro C, Barbato E, Trimarco B, Morisco C. The PARADISE-MI trial: a new opportunity to improve the left ventricular remodelling in reperfused STEMI. ESC Heart Fail. 2022;9(6):3698-3701. DOI: 10.1002/ehf2.14159